Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Brincidofovir Form H vs Form II
NCT05935917Phase 1Completed
- Sponsor
- Emergent BioSolutions
- Start
- May 2023
- Primary completion
- Aug 2023
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of brincidofovir in smallpox (2 arms), sponsored by Emergent BioSolutions. Primary endpoints: Peak Plasma Concentration, Area Under the Curve to Last Measurable Concentration and 5 more. Started May 2023; status: completed.
02
Drugs
brincidofovir
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT05935917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05935917.